| PRODUCT1 | Indication | Pre-clinical | Phase 1/2 | Phase 3 | Commercial | |
|---|---|---|---|---|---|---|
| Talicia® | H. pylori infection2 | APPROVED BY U.S. FDA NOVEMBER 2019 |
||||
| Aemcolo® | Travelers' Diarrhea3 | U.S. EXCLUSIVE LICENSE |
||||
| RHB-104 | Crohn's disease | |||||
| RHB-204 | NTM infections | |||||
| RHB-102 (Bekinda®) |
Gastroenteritis & gastritis | |||||
| IBS-D | ||||||
| RHB-106 | Bowel cleanser | |||||
| Opaganib (Yeliva®) |
Multiple indications | |||||
| RHB-107 | Oncology/GI | |||||
RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company focused on gastrointestinal diseases.